Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).
CSPC Pharmaceutical Group Limited has announced that its independently developed double-stranded small interfering RNA drug, SYH2061 Injection, has received approval from the U.S. FDA to conduct clinical trials in the United States. This siRNA drug, which targets complement component C5, is designed for the treatment of IgA nephropathy and other complement-mediated diseases. The product has shown promising preclinical results, demonstrating superior pharmacological activity, long-lasting therapeutic effects, and a good safety profile, which could enhance the company’s positioning in the pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating in the pharmaceutical industry. The company focuses on developing innovative drugs, with a particular emphasis on new chemical entities and biopharmaceuticals.
YTD Price Performance: 58.81%
Average Trading Volume: 147,049,348
Technical Sentiment Signal: Buy
Current Market Cap: HK$84.89B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.